A carregar...
Mechanistic distinctions between CHK1 and WEE1 inhibition guide the scheduling of triple therapy with gemcitabine
Combination of cytotoxic therapy with emerging DNA damage response inhibitors (DDRi) has been limited by tolerability issues. However, the goal of most combination trials has been to administer DDRi with standard-of-care doses of chemotherapy. We hypothesised that mechanism-guided treatment scheduli...
Na minha lista:
| Publicado no: | Cancer Res |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5985963/ https://ncbi.nlm.nih.gov/pubmed/29735549 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-17-3932 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|